Phase 2B Randomized, Placebo-Controlled Clinical Study of NA-831 for the Treatment of Mild and Moderate Alzheimer’s Disease
Brief Summary
The main purpose of this study is to assess is to evaluate the safety and efficacy of NA-831 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
NA-831™is a small molecule drug that can be administered orally. NA-831 exhibits neuroprotection to protect the brain from further damages.
It has been discovered that in Alzheimer’s patients, the ability to regenerate new neurons in the hippocampus is impaired, causing memory loss and cognitive impairment. NA-831 facilitates neurogenesis restoring memory loss and improve cognitive functions.
NA-831 has demonstarted a proof safety and efficacy in a Phase 2A.
NA-831 has been developed by
Biomed Industries, Inc, of San Jose, California. For more information about NA-831, please
visit the website about NA-831.
For more information in participating in the clinical trials of NA-831 for Alzheimer's Disease,
please contact us or complete the online form below..
Phase 2 Randomized, Placebo-Controlled Clinical Study of NA-931 for the Treatment of Obesity
Brief Summary
Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition
The purpose of this study is to measure the change in body weight with oral daily doses of NA-931 compared with placebo in participants with obesity or overweight with weight- related comorbidities.
NA-931 is an oral quadruple IGF-1, GLP-1, GIP and Glucagon receptor agonist that is being developed as a daily oral adjunct therapy to diet and physical activity to improve weight management in adults who have obesity or are overweight with weight-related comorbidities.
Unlike the peptide GLP-1 receptor agonists approved by regulators to date, NA-931 is a small molecule being developed for daily oral administration.
Study Protocol BIO-931-2024-A is a 13-week Phase 2, multicenter, randomized, double-blind, parallel, placebo-controlled study designed to examine the efficacy and safety of 4 dose levels of QD administered NA-931 compared with QD administered placebo in participants who have obesity or are overweight with weight-related comorbidities.
For more information in participating in the clinical trials of NA-931 for the treatment of Obesity,
please contact us or complete the online form below
Learn more
